Richard Nolan Townsend - 18 Aug 2025 Form 4/A - Amendment Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Youjin Choi, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
18 Aug 2025
Net transactions value
-$5,205
Form type
4/A - Amendment
Filing time
10 Sep 2025, 16:59:33 UTC
Date Of Original Report
20 Aug 2025
Previous filing
20 May 2025
Next filing
16 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Townsend Richard Nolan Chief Executive Officer, Director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Youjin Choi, Attorney-in-Fact 10 Sep 2025 0001995218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Sale $5,205 -1,115 -0.5% $4.67 220,058 18 Aug 2025 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
F2 On August 20, 2025, the reporting person filed a Form 4 which inadvertently reported the disposition of 2,735 securities. In fact, as reported in this amendment, the reporting person disposed of 1,115 shares of Common Stock on August 18, 2025.
F3 Includes 131,092 Restricted Stock Units.